News|Videos|November 27, 2023
EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
Experts discuss the rapidly evolving treatment landscape for EGFR exon 20 insertion lung cancer, highlighting recent advancements in therapies, clinical trial results, and the quest for first-line treatment options, providing valuable insights into managing this unique patient population.
Advertisement
Episodes in this series
Advertisement
Related to this article
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
3
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
4
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
5